Clinical Use of PPARγ Ligands in Cancer
2008
Clinical Use of PPARγ Ligands in Cancer
Sample size: 6
publication
Evidence: moderate
Author Information
Author(s): Jennifer L. Hatton, Lisa D. Yee
Primary Institution: The Ohio State University
Hypothesis
The study investigates the role of PPARγ ligands in the treatment and prevention of various cancers.
Conclusion
PPARγ ligands, particularly thiazolidinediones, show potential in cancer therapy but have limited efficacy in advanced stages of disease.
Supporting Evidence
- PPARγ ligands have shown anticancer effects in various preclinical studies.
- Thiazolidinediones have been evaluated for their potential in treating advanced cancers.
- Clinical trials indicate that PPARγ ligands may induce differentiation in certain cancer cells.
Takeaway
This study looks at how certain medicines can help treat cancer by changing how cancer cells grow and behave.
Methodology
The review summarizes findings from various clinical trials and studies on the effects of PPARγ ligands in cancer treatment.
Limitations
The efficacy of PPARγ ligands appears limited in advanced cancer stages, and results vary across different cancer types.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website